High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma

This publication has 56 references indexed in Scilit:

• Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
  International Journal of Hematology, 2013
• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
  Bone Marrow Transplantation, 2011
• Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma
  Cancer Investigation, 2011
• A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
  Clinical Cancer Research, 2010
• Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
  Haematologica, 2010
• Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
  Bone Marrow Transplantation, 2010
• The molecular classification of multiple myeloma
  Blood, 2006
• Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
  Leukemia, 2005
• High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma
  Leukemia & Lymphoma, 2004
• Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  Bone Marrow Transplantation, 2004